An economic analysis: Is Fidaxomicin worth the cost?

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 603-604

  Shah, Hemal ^a   Doyle, Joseph J ^a   Belletti, Daniel A ^a  

^a Optimer Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

AGE DISTRIBUTION; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; HUMAN; LETTER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNITED STATES; CLOSTRIDIUM INFECTIONS; ECONOMICS; FEMALE; ISOLATION AND PURIFICATION; MALE; PEPTOCLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MALE;

EID: 84893243483     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit773     Document Type: Letter

References (8)

1. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013; 57: 555-61.
2. Cohen SH, Gerding DN, Johnson S, et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
3. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013; 173:1359-67.
4. Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012; 55:351-7.
5. Snydman DR, McDermott LA, Jacobus NV, et al. A US based national sentinel surveillance study for the susceptibility and epidemiology of Clostridium difficile associated diarrheal isolates: baseline CY 2011. In: 52nd ICAAC, San Francisco, CA, 9-12 September 2012.
6. Tufts Medical Center, Institute for Clinical Research and Health Policy Studies: The Center for the Evaluation of Value and Risk in Health. Available at: https://research.tufts-nemc.org/cear4/SearchingtheCEARegistry/SearchtheCEA Registry.aspx. Accessed 8 July 2013.
7. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analyses. Value Health 2006; 9:213-8.
8. Stranges PM, Hutton DW, Collins CD. Costeffectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013; 16:297-304.